Company intelligence / Profile preview

ConTIPI Medical

Ownership: Private
Development stage: Commercial

Overview

ConTIPI Medical has developed two major products from its patent portfolio. The first was a device for stress urinary incontinence that was sold to Kimberly-Clark Worldwide and now marketed as Poise® Impressa. The second product, ProVate, for the non-surgical management of pelvic organ prolapse, has received FDA 510(k) clearance and CE Mark approval. ProVate launched commercially in the U.S. with EVERSANA as commercialization partner.

Therapeutic areas: Women's Health
Modalities: Device
Industry: Therapeutic Medical Devices

Drug pipeline

2 assets

ProVate

Commercial

Indications: Pelvic Organ Prolapse

1 more asset in the full pipeline.

Request access →

Partnerships

EVERSANA (U.S. commercialization partner for ProVate)Indegene (global commercialization/digital strategy partner)

Beyond the preview

Go deeper on ConTIPI Medical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ConTIPI Medical.

Explore the full profile